Login to Your Account

Deals And M&A NEWS

Holding back its wet age-related macular degeneration (AMD) program from the potential $1 billion deal with Biogen Inc. will let Applied Genetic Technologies Corp. (AGTC) reap more value in a collaboration later, as the firm deploys "a better understanding of vector design [that] has come about in the last five to seven years," which allows for "really being able to target the capsid, the promoter, the physical delivery method," CEO Sue Washer told BioWorld Today.

SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC).
HONG KONG – A group of investors, including one from Singapore, have acquired a majority stake in Iceland-based biosimilar and generics maker Alvogen Inc.
More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: